PMID- 15714350
OWN - NLM
STAT- MEDLINE
DCOM- 20050303
LR  - 20191210
IS  - 1618-7598 (Print)
IS  - 1618-7598 (Linking)
VI  - 5
IP  - 3
DP  - 2004 Oct
TI  - A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent 
      ischemic events in acute coronary syndromes in Spain.
PG  - 278-84
AB  - To determine the 16-week health economic outcomes of short-term, intensive 
      lipid-lowering therapy with atorvastatin in patients with acute coronary syndrome 
      (ACS) using unit costs from Spain. The total expected cost per patient and the 
      cost per inpatient event avoided were compared for patients on atorvastatin 80 mg 
      daily versus placebo. The analysis was based on clinical outcome data from the 
      MIRACL study. Clinical outcomes measured in this analysis included: death, 
      cardiac arrest, nonfatal myocardial infarction (MI), fatal MI, angina pectoris, 
      stroke, congestive heart failure (CHF), and surgical or percutaneous coronary 
      revascularizations. Unit costs for outcomes were values using 2001 Diagnosis 
      Related Group (DRG) costs in Spain. The cost of a follow-up visit was added to 
      the cost of each outcome in both groups. In the atorvastatin group, monitoring 
      costs were also added. All direct medical costs were taken from the perspective 
      of the Spanish National Health System during a 16-week period. The hospital cost 
      in the atorvastatin group was <euro> 1,921 per patient, compared to <euro> 1,853 
      in the placebo group. The incremental cost per patient in the atorvastatin group 
      was <euro> 67.47, corresponding to a cost per inpatient event avoided of <euro> 
      1,760. The cost of atorvastatin for 16 weeks was <euro> 128. Forty-seven percent 
      of this cost of atorvastatin was offset by the cost savings obtained through the 
      reduction of number of events in the atorvastatin group. In Spain, the intensive 
      short-term use of atorvastatin in patients with ACS has a favorable 
      cost-effectiveness. The direct cost of the drug was largely offset by the 
      associated reduction in costs for treating fewer cardiovascular events.
FAU - Gomez-Gerique, Juan Antonio
AU  - Gomez-Gerique JA
AD  - Clinic Biochemistry Department, Hospital Fundacion Jimenez Diaz, Madrid, Spain.
FAU - Casciano, Roman
AU  - Casciano R
FAU - Stern, Lee
AU  - Stern L
FAU - Rejas, Javier
AU  - Rejas J
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - Germany
TA  - Eur J Health Econ
JT  - The European journal of health economics : HEPAC : health economics in prevention 
      and care
JID - 101134867
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Placebos)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Acute Disease
MH  - Angina, Unstable/*drug therapy/*economics/therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Anticholesteremic Agents/administration & dosage/*economics/*therapeutic use
MH  - Atorvastatin
MH  - Coronary Artery Bypass
MH  - Cost Savings
MH  - Cost-Benefit Analysis
MH  - Diagnosis-Related Groups/economics
MH  - Double-Blind Method
MH  - *Economics, Pharmaceutical
MH  - Heptanoic Acids/administration & dosage/*economics/*therapeutic use
MH  - Humans
MH  - Multicenter Studies as Topic
MH  - Myocardial Infarction/*drug therapy/*economics/therapy
MH  - Placebos
MH  - Pyrroles/administration & dosage/*economics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recurrence
MH  - Risk Factors
MH  - Spain
MH  - Syndrome
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2005/02/17 09:00
MHDA- 2005/03/04 09:00
CRDT- 2005/02/17 09:00
PHST- 2005/02/17 09:00 [pubmed]
PHST- 2005/03/04 09:00 [medline]
PHST- 2005/02/17 09:00 [entrez]
AID - 10.1007/s10198-003-0222-1 [doi]
PST - ppublish
SO  - Eur J Health Econ. 2004 Oct;5(3):278-84. doi: 10.1007/s10198-003-0222-1.